Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Canrun Hu

2 papers in the library · 14 citations · publishing 2025-2026

Papers

Inulin alleviates chronic ketamine-induced impairments in memory and prepulse inhibition by regulating the gut microbiota, inflammation, and kynurenine pathway.

International journal of biological macromolecules March 1, 2025 Zhilong Xu, Haoyang Lu, Canrun Hu et al. 14 citations

Chronic ketamine exposure for 14 days disrupts the gut microbiota, increases gut permeability, and activates an inflammatory pathway (TLR4-NF-κB-NLRP3) in the hippocampus, leading to neuroinflammation, neuronal damage, and activation of the tryptophan-kynurenine-kynurenic acid pathway in the hippocampus, blood, and feces. These changes result in deficits in recognition memory and prepulse inhibition (PPI). Treatment with inulin restores gut dysbiosis by increasing Turicibacter and Ileibacterium and decreasing Alistipes, Alloprevotella, Desulfovibrio, and Parasutterella, improves gut barrier integrity, suppresses the inflammatory pathway, reduces neuroinflammation and neuronal damage, and inhibits the tryptophan-kynurenine-kynurenic acid metabolism, thereby alleviating memory and PPI impairments. Inulin may be a potential intervention for cognitive deficits linked to chronic ketamine use or schizophrenia.

Inulin ameliorates chronic ketamine-induced anxiety-like behaviors and impairments in spatial learning and memory: involvement of gut microbiota, microbial metabolite short-chain fatty acids, and the BDNF-TrkB-ERK1/2-CREB pathway

Frontiers in Microbiology April 7, 2026 Zhilong Xu, Jie Zhang, Canrun Hu et al.

Chronic ketamine exposure for 28 days in an animal model disrupts gut microbiota, reduces short-chain fatty acids (SCFAs) and BDNF signaling, damages neurons, and causes anxiety-like behaviors, prepulse inhibition deficits, and spatial learning and memory impairments. Dietary inulin reversed these gut microbiota changes, increased SCFAs, repaired gut barrier damage, and restored BDNF-TrkB-ERK1/2-CREB signaling, which improved the behavioral deficits. Inulin may be a promising candidate for treating chronic ketamine-associated behavioral symptoms and schizophrenia with dysbiosis.